Changeflow GovPing Courts & Legal smaXtec Inc. v. ST Reproductive Technologies - ...
Priority review Enforcement Amended Final

smaXtec Inc. v. ST Reproductive Technologies - Director Review Order

Favicon for www.uspto.gov USPTO Director Review Status
Filed April 2nd, 2026
Detected April 7th, 2026
Email

Summary

The USPTO Director reviewed ST Reproductive Technologies' Final Written Decision (Paper 49) in IPR 2024-00875 and found procedural deficiencies warranting further review. The Director determined the PTAB overlooked Patent Owner's arguments on claim 18, and made inconsistent findings as to claims 6, 19, and 20. Both parties agreed the Board erred. The Director has delegated this matter to a Delegated Rehearing Panel (DRP) to reconsider these issues within 45 days.

What to do next

  1. Monitor for DRP decision within 45 days of this Order
  2. Prepare for potential impact on patent claims 4, 6, and 18-20
  3. Review internal patent portfolio for similar claim vulnerabilities

Source document (simplified)

DirectorPTABDecisionReview@uspto.gov Paper 52 571.272.7822 Date: April 2, 2026 UNITED STATES PATENT AND TRADEMARK OFFICE ____________ BEFORE THE OFFICE OF THE UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE ____________ SMAXTEC INC. and SMAXTEC ANIMAL CARE GMBH, Petitioner,

ST REPRODUCTIVE TECHNOLOGIES, LLC, Patent Owner. ________________ ________________

Before JOHN A. SQUIRES, Under Secretary of Commerce for Intellectual

Property and Director of the United States Patent and Trademark Office.

ORDER

ST Reproductive Technologies, LLC ("Patent Owner") filed a request for Director Review of the Final Written Decision ("Decision," Paper 49) in the above-captioned case, and smaXtec Inc. and smaXtec Animal Care GmbH (collectively "Petitioner") filed an authorized response. See Paper 50 ("Request"); Paper 51 ("Response"). Patent Owner argues that the Decision should be reversed as to claims 4, 6, and 18-20 because the Board failed to consider and resolve Patent Owner's arguments as to these claims, relied on arguments and concessions that Patent Owner did not make, and made inconsistent findings. DR Request 1. For its part, Petitioner is in agreement that the Decision did not consider all of Patent Owner's arguments as to claim 18, as well as included potentially inconsistent findings as to claims 6, 19, and 20. DR Resp. 11-

  1. However, Petitioner does not agree with Patent Owner's additional arguments for reversal. Having considered the Request and Response, I find the Decision warrants further review and that a Delegated Rehearing Panel ("DRP") is the appropriate body to give reconsideration to the Board's work, which goes to the integrity of the patent system. Indeed, as the parties are in agreement that Board erred in finding that Patent Owner "does not separately argue" claim 18, "instead relying on its prior argument against claim 1," Decision 48, 81, and also that Board's findings as to claims 6, 19, and 20 need to be reconciled, compare Decision 42-43, with id. at 48-49, convening a DRP is appropriate. Accordingly, I delegate Director Review of the Decision to the DRP for a review and determination as to whether the Board overlooked, misapprehended, or otherwise erred as to these issues, as Patent Owner argues.

Absent good cause, the DRP shall issue a decision within 45 days of this Order. It is: ORDERED that the request for Director Review is delegated to a DRP.

For PETITIONER: Jeffrey Plies Blaine Hackman DECHERT LLP jeffrey.plies@dechert.com blaine.hackman@dechert.com Brian Buroker Benjamin Hershkowitz Nathan Curtis GIBSON, DUNN, CRUTCHER LLP bburoker@gibsondunn.com bhershkowitz@gibsondunn.com ncurtis@gibsondunn.com For PATENT OWNER: Daniel Moffett Megan Mahoney AKIN GUMP STRAUSS HAUER & FELD LLP dmoffett@akingump.com mmahoney@akingump.com

Named provisions

Inter Partes Review Director Review Procedures

Get daily alerts for USPTO Director Review Status

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Classification

Agency
USPTO
Filed
April 2nd, 2026
Compliance deadline
May 17th, 2026 (40 days)
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
IPR2024-00875, Paper 52
Docket
IPR2024-00875

Who this affects

Applies to
Patent owners Petitioners
Industry sector
3254.1 Biotechnology
Activity scope
Patent validity challenges IPR proceedings Administrative tribunal review
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare

Get alerts for this source

We'll email you when USPTO Director Review Status publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.